Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- Status
- RECRUITING
- Phase
- PHASE2
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
- Status
- TERMINATED
- Phase
- PHASE2
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2